DOCSLIB.ORG

California Breast Cancer Research Program Special Research Initiatives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
California Breast Cancer Research Program Special Research Initiatives Identifying Gaps in Breast Cancer Research California Breast Cancer Research Program Special Research Initiatives Identifying gaps in breast cancer research: Addressing disparities and the roles of the physical and social environment Editors Julia G. Brody, PhD Executive Director Silent Spring Institute Marion (Mhel) H.E. Kavanaugh-Lynch, MD, MPH Director California Breast Cancer Research Program Olufunmilayo I (Funmi) Olopade, MD Walter L. Palmer Distinguished Service Professor of Medicine University of Chicago Medical Center Susan Matsuko Shinagawa Breast Cancer and Chronic Pain Survivor/Advocate, Intercultural Cancer Council; Asian and Pacific Islander National Cancer Survivors Network Sandra Steingraber, PhD Author and Distinguished Visiting Scholar Ithaca College David R. Williams, PhD Department of Society, Human Development and Health Harvard School of Public Health Front Matter DRAFT 8/11/07 Page 1 California Breast Cancer Research Program Table of Contents Preface Introduction Section I: Exposures from the Physical Environment and Breast Cancer Overarching Issues A. Secondhand Smoke B. Environmental Chemicals/Pollutants 1. Air Pollutants, Fuels and Additives 2. Persistent Organic Pollutants 3. Polybrominated Flame Retardants 4. Pesticides 5. Solvents and industrial chemicals 6. Water Contaminants 7. Hormones in Food 8. Metals 9. Exposures from Polyvinyl Chloride 10.Bisphenol A C. Compounds in Personal Care Products D. Pharmaceuticals E. Infectious agents F. Ionizing Radiation G. Electric and Magnetic Fields H. Light at night I. Vitamin D/Sunlight Section II: Disparities in Breast Cancer: Domains of Individual-level Social Inequality A. Race/Ethnicity B. Sexual Minority Women C. Disability Status D. Culture E. Health Insurance Section III: Neighborhood Context and Breast Cancer Front Matter DRAFT 8/11/07 Page 2 Identifying Gaps in Breast Cancer Research Acknowledgements The California Breast Cancer Research Program would like to acknowledge the assistance from the following individuals who participated in the development of these chapters. Any inaccuracies, however, are solely the responsibility of CBCRP. Please feel free to send comments about any chapter to [email protected]. Deborah Bowen, PhD, Professor, Social Behavioral Sciences, Boston University Judy Bradford, PhD, Director, Community Health Research, Virginia Commonwealth University Linda Burhansstipanov, MSPH, DrPH, Grants Director, Native American Cancer Research Christina A. Clark, PhD, Research Scientist, Northern California Cancer Center Lisa Clarke, MS, Research Associate, Northern California Cancer Center Richard W. Clapp, DSc, MPH, Professor, School of Public Health, Boston University Melissa B. Davis, PhD, Postdoctoral Fellow/Scholar, Center for Interdisciplinary Health Disparities Research, University of Chicago Suzanne E. Fenton, PhD, Research Biologist, Reproductive Toxicology Division, U.S. Environmental Protection Agency, Maria Feychting, PhD, Professor, Institute of Environmental Medicine, Karolinska Institute Scarlett Lin Gomez, PhD, Research Scientist, Northern California Cancer Center Robert B. Gunier, MPH, Research Associate, Northern California Cancer Center Dawn Hershman, MD, Assistant Professor of Medicine, Columbia University Chanita Hughes Halbert, PhD, Associate Professor University of Pennsylvania Susan E. Hurley, MPH, Research Associate, Northern California Cancer Center Esther M. John, PhD, Research Scientist, Northern California Cancer Center Lovell Jones, PhD, Director, M. D. Anderson’s Center for Research on Minority Health Sue Joslyn, PhD, Professor of Epidemiology, Associate Dean of Graduate Academic Affairs, University of Northern Iowa Marjorie Kagawa-Singer, PhD, RN, MN, MA, Professor, School of Public Health and School of Asian American Studies, University of California, Los Angeles Judith Salmon Kaur, MD, Medical Director, Professor of Oncology, Native American Programs, Mayo Comprehensive Cancer Center Steve Kaye, PhD, Associate Professor, University of California, San Francisco Charles Land, PhD, Senior Investigator, National Cancer Institute Robert Millikan, PhD, Professor, University of North Carolina, Chapel Hill Rachel Morello-Frosch, MPH, PhD, Associate Professor, Center for Environmental Studies, Department of Community Health, School of Medicine, Brown University Front Matter DRAFT 8/11/07 Page 3 California Breast Cancer Research Program Kirsten Moysich, PhD, Associate Professor, Roswell Park Cancer Institute Margaret Nosek, PhD, Professor, Baylor College of Medicine Sharon Perry, PhD, Senior Research Scientist, School of Medicine, Stanford University Blase N. Polite, MD, MPP, Instructor of Medicine, University of Chicago Anh-Thu Quach, MPH, Research Associate, Northern California Cancer Center Peggy Reynolds, PhD, Senior Research Scientist, Northern California Cancer Center Stephanie Robert, PhD, Associate Professor, School of Social Work, University of Wisconsin- Madison Ruthann Rudel, MS, Senior Scientist, Toxicologist, Silent Spring Institute Theresa M. Saunders, BA, Research Program Manager, Northern California Cancer Center Ted Schettler, MD, MPH, Science Director, Science & Environmental Health Network Richard Stevens, PhD, Cancer Epidemiologist, Department of Community Medicine and Health Care, University of Connecticut Joseph Thornton, PhD, Associate Professor, Center for Ecology & Evolutionary Biology, University of Oregon Julie Von Behren, MPH, Research Associate, Northern California Cancer Center David Wallinga, MD, MPA, Director of the Food and Health Program, Institute for Agriculture and Trade Policy Barbour Warren, PhD, Research Associate, Program on Breast Cancer & Environmental Risk Factors, Cornell University Tom Webster, DSc, Associate Professor, Environmental Health, School of Public Health, Boston University Mary Wolff, PhD, Professor, Mount Sinai Medical Center Staff and Consultants Janna Cordeiro, MPH, Coordinator of Special Projects Elizabeth Day, Program Assistant Judy Maclean, BA, Editorial Consultant Katherine McKenzie, PhD, Manager-External Relations; Biomedical Research Administrator Marj Plumb, DrPH, MNA, Senior Consultant, Plumbline Coaching and Consulting, Inc. Patrice Sutton, MPH, Technical Consultant Catherine Thomsen, MPH, Project Lead Front Matter DRAFT 8/11/07 Page 4 Identifying Gaps in Breast Cancer Research • To conduct research that will provide PREFACE recommendations to advocacy organizations and policy makers for • What role does the environment play in evidence-based change. breast cancer? • To stimulate more research into the • Why do some groups of women bear a environment-breast cancer connection and greater burden of this disease than others? the reasons why some groups of women The answers to these questions have thus far bear a greater burden of breast cancer. eluded scientists, yet answering them could lead to We plan to identify and involve California great progress against breast cancer. Recognizing organizations and institutions who can join forces the need for more research into these questions, and increase the resources available to conduct the California Breast Cancer Research Program this research. (CBCRP) is launching our Special Research Initiatives, a five-year effort to find answers that This report is not a comprehensive review of all will push breast cancer research forward. research on the environment-breast cancer connection or the reasons why some groups of We are setting aside 30 percent of our funds over women bear more of the burden of the disease. It five years for the Special Research Initiatives, is instead a review of existing research—gathered approximately $18 million. To select the research from widely scattered sources—pointed toward that will lead to the most progress against breast discovering research areas that show some cancer, we are following a carefully-crafted, two- connection with the disease, and recommending year, publicly-accessible strategy development further investigations that are likely to make the process. An initial step in the process is this most difference toward eliminating the death and report reviewing previous research. suffering caused by breast cancer. We are embarking on the Special Research The Need for This Research Initiatives because research has been conducted for decades, and yet too many women are being Breast cancer is a complex disease. Despite diagnosed with breast cancer, living with the decades of intensive research, its causes and basic threat of a recurrence, and dying. There is no biology remain unclear. From the 1940s until action women can take to assure they won't get very recently, the U.S. breast cancer rate has been breast cancer. Our goals are: rising, and this increase is not explained by better detection methods. • To initiate research that will point to actions that can be taken to reduce the Scientific studies have uncovered a number of risk burden of breast cancer factors for breast cancer. Some of these risk factors can be modified by individuals to lower Preface DRAFT 6/19/07 Page 1 California Breast Cancer Research Program their risk, and others cannot. One known risk population groups could not only lead to a factor is a family history of the disease, which decrease in inequality among groups of women raises a woman's risk. This can't be modified by with breast cancer, but also reveal crucial individuals. Another known risk factor is not information about the disease itself. having children or having children later in life. Although this can be modified by individuals,
Load more

Recommended publications
  • Chapter 1. Epidemiology of Hypertension
    Hypertension Research (2009) 32, 6–10 & 2009 The Japanese Society of Hypertension All rights reserved 0916-9636/09 $32.00 www.nature.com/hr GUIDELINES (JSH 2009) Chapter 1. Epidemiology of hypertension Hypertension Research (2009) 32, 6–10; doi:10.1038/hr.2008.9 POINT 1 Similar values were also reported in the quick report of the National Health and Nutrition Survey in 2006. The number of hypertensive 1. The number of hypertensive people in Japan has reached Japanese is expected to increase further with the growth in the elderly approx 40 million. population. 2. The average blood pressure levels of the Japanese decreased markedly following a peak in 1965–1990. This decrease 2) CHANGES IN AVERAGE BLOOD PRESSURE LEVELS OF THE closely coincided with the decrease in mortality rate due to JAPANESE stroke in Japan. In Japan, with the successful management of infections following 3. Morbidity and mortality rates due to diseases such as stroke, World War II, the age-adjusted mortality rate due to stroke increased myocardial infarction, heart disease and chronic renal dis- rapidly and reached a peak in 1965. It then decreased rapidly until ease increase with elevating blood pressure. The effects of 1990, and the life expectancy of the Japanese became the longest in the hypertension are more specific to stroke than to myocardial world.1 During this period, the morbidity rate from stroke decreased, infarction, and, in Japan, the morbidity rate due to stroke is contributing greatly to the reduction in mortality rate due to stroke, still higher than that due to myocardial infarction.
    [Show full text]
  • Chapter 13. Secondary Hypertension
    Hypertension Research (2014) 37, 349–361 & 2014 The Japanese Society of Hypertension All rights reserved 0916-9636/14 www.nature.com/hr GUIDELINES (JSH 2014) Chapter 13. Secondary hypertension Hypertension Research (2014) 37, 349–361; doi:10.1038/hr.2014.16 OVERVIEW AND SCREENING approximately 5–10% of hypertensive patients,984,985 and it is the most Hypertension related to a specific etiology is termed secondary frequent in endocrine hypertension. In addition, frequent etiological hypertension, markedly differing from essential hypertension, of factors for secondary hypertension include renal parenchymal hyper- which the etiology cannot be identified, in the condition and tension and renovascular hypertension. A study reported that sleep therapeutic strategies. Secondary hypertension is often resistant hyper- apnea syndrome was the most frequent factor for secondary hyper- tension, for which a target blood pressure is difficult to achieve by tension.517 The number of patients with secondary hypertension standard treatment. However, blood pressure can be effectively may further increase with the widespread diagnosis of sleep apnea reduced by identifying its etiology and treating the condition. There- syndrome. fore, it is important to suspect secondary hypertension and reach an Generally, the presence of severe or resistant hypertension, juvenile appropriate diagnosis. hypertension and the rapid onset of hypertension suggest the possi- Frequent etiological factors for secondary hypertension include bility of secondary hypertension. In such hypertensive patients, a close renal parenchymal hypertension, primary aldosteronism (PA), reno- inquiry on medical history, medical examination and adequate vascular hypertension and sleep apnea syndrome. Renal parenchymal examinations must be performed, considering the possibility of hypertension is caused by glomerular diseases, such as chronic secondary hypertension.
    [Show full text]
  • Endocrine Abstracts Vol 44
    Endocrine Abstracts November 2016 Volume 44 ISSN 1479-6848 (online) Society for Endocrinology BES 2016 7–9 November 2016, Brighton, UK published by Online version available at bioscientifica www.endocrine-abstracts.org Volume 44 Endocrine Abstracts November 2016 Society for Endocrinology BES 2016 7–9 November, The Brighton Centre Brighton, UK EDITORS The abstracts submitted were marked by the Abstract Marking panel selected by the Programme Committee Programme Committee S Pearce (Chair of the Programme Committee) G Lavery (Programme Co-ordinator) R Semple (Programme Co-ordinator) Members R Andrew N Gittoes S Miczuk E Crowne K Hardy S Pearce E Davies P King L Shepherd M Druce A Logan A Toogood W Farrell C McCardle Co-opted members H Christian V Smith (Birmingham) H Simpson Abstract Marking Panel James Ahlquist Julian Davis Brian Keevil Salman Razvi Ramzi Ajjan Colin Dayan Nikki Kieffer Martin Read Ruth Andrew Miguel DeBono Marta Korbonits Aled Rees Rob Andrews Waljit Dhillo Nils Krone Philippa Saunders Weibke Arlt Will Drake Gareth Lavery Peter Selby Mo Aye Colin Duncan Graham Leese Lisa Shepherd Simon Aylwin William Farrell Jacques Lenders Helen Simpson John Ayuk Rob Fowkes Andy Levy Vicki Smith Tom Barber Jayne Franklyn Miles Levy Roland Stimson Julian Barth Bill Fraser Stafford Lightman Abd Tahrani Andy Bates William Fraser Craig A McArdle Tricia Tan Kristien Boelaert Marie Freel Phil McTernan Christina Thirlwell Pierre Bouloux Neil Gittoes Daniel Morganstein Tony Toft Paul Carroll Helena Gleeson Damian Morris Jeremy Tomlinson Karen Chapman Mark Gurnell Kevin Murphy Mark Vanderpump Krishna Chatterjee Fadil Hannan Rob Murray Gwen Wark Tim Cheetham Pippa Hanson John Newell-Price Tony Weetman Juliet Compston Steve Hillier Simon Pearce Melissa Westwood Sue Cox Megan Holmes Colin Perry Anna Crown Andy James Pat Pickett Eleanor Davies Niki Karavitaki Richard Quinton Society for Endocrinology BES 2016 Corporate supporters The Society for Endocrinology would like to thank its Corporate Supporters for their generous financial assistance.
    [Show full text]
  • Surgical Treatment of Hypertension Wessel Vorselaars
    SURGICAL TREATMENT OF HYPERTENSION OF HYPERTENSION SURGICAL TREATMENT SURGICAL TREATMENT OF HYPERTENSION Preoperative work-up and surgical treatment of primary aldosteronism in current daily practice WESSEL VORSELAARS WESSEL VORSELAARS SURGICAL TREATMENT OF HYPERTENSION Preoperative work-up and surgical treatment of primary aldosteronism in current daily practice WESSEL VORSELAARS Surgical treatment of hypertension Preoperative work-up and surgical treatment of primary aldosteronism in current daily practice PhD thesis, Utrecht University, the Netherlands © Wessel Mathieu Corneel Marie Vorselaars, 2019 ISBN 978-94-6380-445-5 Layout and design wenz iD || Wendy Schoneveld Printed by ProefschriftMaken || www.proefschriftmaken.nl All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without prior written permission from the author. The copyright of the papers that have been published or have been accepted for publication, has been transferred to the concerning journal. Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged. Other sponsors: ChipSoft and RG Wedding Photography (www.rgphotography.nl) SURGICAL TREATMENT OF HYPERTENSION Preoperative work-up and surgical treatment of primary aldosteronism in current daily practice DE CHIRURGISCHE BEHANDELING VAN HYPERTENSIE De preoperatieve work-up en de chirurgische behandeling van primair hyperaldosteronisme in de hedendaagse praktijk Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof. dr. H.R.B.M. Kummeling, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 19 september 2019 des middags te 12.45 uur door Wessel Mathieu Corneel Marie Vorselaars geboren op 24 mei 1990 te Utrecht Promotoren: Prof.
    [Show full text]
  • 16Th July 2001
    AUSTRALASIAN ASSOCIATION OF CLINICAL BIOCHEMISTS INC 5/85 Bourke Rd, Alexandria NSW, 2015 Telephone: +61 2 9669 6600 Facsimile: +61 2 9669 6607 Email: [email protected] Draft Guideline Title Harmonisation of Endocrine Dynamic Testing (HEDT) Document Number: 2018 DGD02 Publication date: Draft for comment September 2018 Next review date: Owner: ESA/AACB/RCPA HEDT Working Party This draft manual for Harmonisation of Endocrine Dynamic Testing is a joint initiative from ESA/AACB/RCPA and is now open for comment and feedback for 90 days. Information provided is a guide only and needs to be verified and modified according to local procedures (e.g. patient consent, sample type, name of test set). A separate paediatric endocrine dynamic testing protocol is in progress with the HDET-P working party. Please direct comments to the chair of the HEDT working party: Dr Cherie Chiang ([email protected]) with the subject heading " HEDT feedback" 2018 DGD02 Harmonisation of Endocrine Dynamic Testing (HEDT) This manual is a joint initiative from ESA/AACB/RCPA and is freely available as a resource for Endocrinologists and Biochemists. Information provided is a guide only and needs to be verified and modified according to local procedures (e.g. patient consent, sample type, name of test set). Queries can be directed to the chair of the HEDT working party. A separate paediatric endocrine dynamic testing protocol is in progress with the HDET-P working party. 2018 DGD02 Page 1 Table of Contents HEDT Working Group Members: ...........................................................................................................4
    [Show full text]
  • Primary Hyperaldosteronism: Screening, Diagnosis, and Management for the Clinician Eugene T
    Archives of Diabetes and Endocrine System ISSN 2638-4981 Volume 1, Issue 2, 2018, PP:39-48 Primary Hyperaldosteronism: Screening, Diagnosis, and Management for the Clinician Eugene T. Van, DO1, Winnie Nhan, DO2*, Kristyn Perry, DO3, Azadeh Brumand, DO4 Serena Shen, DO5, Kelvin L. Tran, DO6, Quang T. Nguyen, DO, FACP, FACE, FTOS7 1, 2, 3, 4, 6 5 Department of Internal Medicine, Valley Hospital Medical Center, Las Vegas, NV. 7 Department of Family Medicine, Valley Hospital Medical Center, Las Vegas, NV. Medical Director, Las Vegas Endocrinology, Clinical Associate Professor, Clinical Education, AZCOM, and *Corresponding Author: Winnie Nhan, DO, Department of Internal Medicine, Valley Hospital Medical Center, Las Adjunct Associate Professor of Endocrinology, Touro University Nevada. Vegas, NV, USA. Abstract Primary hyperaldosteronism (PA) is the most common secondary, non-iatrogenic cause of hypertension. This condition is associated with significant risk of morbidity and mortality, yet it is often unrecognized and undiagnosed in the primary care setting. Screening with the aldosterone to renin ratio (ARR) should be considered in patients with resistant hypertension, defined as blood pressure >140/90 mmHg despite the use of three different classes of antihypertensive medications, including a diuretic. The goal of this review is to inform the primary care clinician of the current guideline recommendations for screening, confirming, subtyping, and treating primary hyperaldosteronism. Introduction hypertension is frequently recognized and treated Hypertension affects up to 75 million adults in America, in the primary care setting, secondary hypertension with an estimated cost of $46 billion in annual health is often overlooked and remains untreated. The care utilization, prescription medications, and missed most common cause of secondary hypertension work days (11).
    [Show full text]
  • Syndrome. See VIP-Oma of the Pancreas ACTH. See Adrenocorticot
    Index A occult tumors in, 52-53 Abdomen, computed tomography of, 29f, 30f, 51 Adrenogenital syndrome, 38 Achlorhydria (WDHR) syndrome. See VIP-oma of Aldosterone, effects of, 36 the pancreas Aldosterone and primary aldosteronism (Conn's ACTH. See Adrenocorticotropic hormone syndrome),155-159 Addison's disease, 31, 133 aldosterone suppression tests, 157-158 Adrenal carcinoma, arteriography of, 43f determination of plasma aldosterone precursors, Adrenal cortex 158 aldosterone-producing tumors of, 36 determination of plasma and urinary aldosterone diseases of, 33-38 levels, 156 Adrenal cortical carcinomas, 42-43 determination of plasma renin activity or Adrenal glands, 28-32 concentration, 155-156 adrenal scintigraphy in, 28 determination of plasma/serum electrolytes, 155 close interaction between gonads and, 21 individual basal levels, 158f computed tomography of, 28-30, 32 postural stimulation test, 156-157 in Cushing's disease, 35f response to spironolactone trial, 159 in macro nodular hyperplasia, 35 twenty-four-hour urinary aldosterone excretion magnetic resonance imaging (MRI) in, 30-32 rates, 158f malignant tumors of, 42-43 Aldosteronism, treatment of, 38 single adenoma of, 50f Aldosteronoma, in Conn's syndrome, 37f ultrasonography in, 28, 32 Amine-precursor uptake and decarboxylation venous sampling in, 32 (APUD),75 Adrenal hemorrhage, 31 Androgen-producing adrenal neoplasias, 162-163 Adrenal hormone excess, 36-38 Androgen-producing tumors, 38 Adrenal hyperplasia, 34f Androgen-secreting ovarian tumors, 25t Adrenal imaging, indications
    [Show full text]
  • Role of Endogenous ACTH on Circadian Aldosterone Rhythm in Patients with Primary Aldosteronism
    T Sonoyama et al. ACTH on aldosterone secretion 1–7 3:173 Research in aldosteronism Open Access Role of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism Takuhiro Sonoyama, Masakatsu Sone, Naohisa Tamura, Kyoko Honda, Correspondence Daisuke Taura, Katsutoshi Kojima, Yorihide Fukuda, Naotetsu Kanamoto, should be addressed Masako Miura, Akihiro Yasoda, Hiroshi Arai, Hiroshi Itoh and Kazuwa Nakao to M Sone Email Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, sonemasa@kuhp. 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan kyoto-u.ac.jp Abstract We recently reported that stimulation with high-dose ACTH caused different responses in Key Words terms of aldosterone secretion in aldosterone-producing adenomas (APAs) and idiopathic " primary hyperaldosteronism hyperaldosteronism (IHA) in patients with primary aldosteronism (PA). However, the role of " hypertension endogenous ACTH in aldosterone secretion in PA has not been systematically evaluated. " adrenal gland In this study, we examined diurnal changes in plasma aldosterone concentration (PAC), and " adrenocorticotropic hormone changes in PAC after dexamethasone administration in patients with suspected PA, in order " clinical medicine to evaluate the effect of endogenous ACTH on aldosterone secretion. Seventy-three patients Endocrine Connections admitted to Kyoto University Hospital with suspected PA were included. The patients were classified into non-PA, IHA, and APA groups according to the results of captopril challenge test and adrenal venous sampling. PAC at 0900 h (PAC0900), 2300 h (PAC2300), and after 1-mg dexamethasone suppression test (PACdex) was measured and compared among the three groups. The PAC2300/PAC0900 and PACdex/PAC0900 ratios were also analyzed.
    [Show full text]
  • Clinical and Investigative Endocrinology and Diabetes
    APRIL 2017 VOLUME 23 SUPPLEMENT 3 Clinical and Investigative Endocrinology and Diabetes 2017 AACE ANNUAL SCIENTIFIC & CLINICAL CONGRESS ABSTRACTS ABSTRACT CATEGORIES 1 Adrenal Disorders 121 Obesity 29 Diabetes Mellitus/Prediabetes 131 Other 83 Hypoglycemia 161 Pituitary Disorders/Neuroendocrinology 95 Lipid/Cardiovascular Disorders/Hypertension 227 Reproductive Endocrinology 99 Metabolic Bone Disease 247 Thyroid Disease OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN COLLEGE OF ENDOCRINOLOGY • WWW.AACE.COM ABSTRACTS Table of Contents Adrenal Disorders . 1 Diabetes Mellitus/Prediabetes . 29 Hypoglycemia . 83 Lipid/Cardiovascular Disorders/Hypertension . 95 Metabolic Bone Disease . 99 Obesity . 121 Other . 131 Pituitary Disorders/Neuroendocrinology . .161 Reproductive Endocrinology . 191 Thyroid Disease . 209 Author Index . 263 Notes . 277 ABSTRACTS ADRENAL DISORDERS the presence of gonads. Primary or ACTH-independent bilateral macronodular adrenal hyperplasia (BMAH) is Abstract #100 usually associated with Cushing’s syndrome and suppressed ACTH. In CAH on the other hand, steroidogenesis is ACTH AUTONOMOUS MASSIVE MACRONODULAR mediated and levels are usually elevated >70. Our patient had ADRENALS IN THE SETTING OF CONGENITAL an ACTH in the normal range indicating that the adrenals ADRENAL HYPERPLASIA seemed to have become partially autonomous. The presence of long-term untreated CAH caused the adrenals over time to Joyce George, MD, Betul Hatipoglu, MD, Adi Mehta, MD become autonomous and escape the control of ACTH. Conclusion: A very interesting case depicting the co- Cleveland Clinic Foundation occurrence of BMAH and CAH. BMAH is one situation where one should check a 17-OHP level. Case Presentation: A 74 year old male presented to our Endocrinology clinic for workup of incidentally found Abstract #101 adrenal enlargement and nodules on CT.
    [Show full text]
  • Coincidence of Large Adrenal Cyst and Prominent Hyporeninemic Hyperaldosteronism
    Hindawi Case Reports in Endocrinology Volume 2021, Article ID 8860498, 6 pages https://doi.org/10.1155/2021/8860498 Case Report Coincidence of Large Adrenal Cyst and Prominent Hyporeninemic Hyperaldosteronism Takaaki Sakaue,1 Yosuke Okuno ,1 Kosuke Mukai ,1 Shingo Fujita,1 Junji Kozawa,1 Hitoshi Nishizawa,1 Taka-Aki Matsuoka,1 Hiromi Iwahashi,1,2 Maeda Norikazu,1,3 Yuto Yamazaki,4 Hironobu Sasano,4 Michio Otsuki ,1 and Iichiro Shimomura1 1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan 2Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan 3Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan 4Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan Correspondence should be addressed to Yosuke Okuno; [email protected] and Michio Otsuki; otsuki@ endmet.med.osaka-u.ac.jp Received 21 August 2020; Revised 28 January 2021; Accepted 11 February 2021; Published 20 February 2021 Academic Editor: Mihail A. Boyanov Copyright © 2021 Takaaki Sakaue et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A 67-year-old Japanese woman who had end-stage renal disease was referred to our hospital for kidney transplantation. Ab- dominal CTrevealed a large adrenal mass with inhomogeneity. She had a history of hospitalization for stroke and heart failure and exhibited prominent hyporeninemic hyperaldosteronism. Histological examination of the resected tumor with anti-CYP11B2 antibody indicated that she had a vascular endothelial cyst with primary aldosteronism (PA) due to multiple adrenocortical micronodules.
    [Show full text]
  • Clinical Characterization of Patients with Primary Aldosteronism Plus
    Yasuda et al. BMC Endocrine Disorders (2020) 20:9 https://doi.org/10.1186/s12902-020-0490-0 RESEARCH ARTICLE Open Access Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome Shigemitsu Yasuda1* , Yusuke Hikima1, Yusuke Kabeya2, Shinichiro Iida1, Yoichi Oikawa1, Masashi Isshiki1, Ikuo Inoue1, Akira Shimada1 and Mitsuhiko Noda1,3 Abstract Background: Primary aldosteronism (PA) plus subclinical Cushing’s syndrome (SCS), PASCS, has occasionally been reported. We aimed to clinically characterize patients with PASCS who are poorly profiled. Methods: A population-based, retrospective, single-center, observational study was conducted in 71 patients (age, 58.2 ± 11.2 years; 24 males and 47 females) who developed PA (n = 45), SCS (n = 12), or PASCS (n = 14). The main outcome measures were the proportion of patients with diabetes mellitus (DM), serum potassium concentration, and maximum tumor diameter (MTD) on the computed tomography (CT) scans. Results: The proportion of DM patients was significantly greater in the PASCS group than in the PA group (50.0% vs. 13.9%, p < 0.05), without a significant difference between the PASCS and SCS groups. Serum potassium concentration was significantly lower in the PASCS group than in the SCS group (3.2 ± 0.8 mEq/L vs. 4.0 ± 0.5 mEq/L; p < 0.01), without a significant difference between the PASCS and PA groups. Among the 3 study groups of patients who had a unilateral adrenal tumor, MTD was significantly greater in the PASCS group than in the PA group (2.7 ± 0.1 cm vs. 1.4 ± 0.1 cm; p < 0.001), without a significant difference between the PASCS and SCS groups.
    [Show full text]
  • Endocrine Hypertension: a Practical Approach
    Adv Exp Med Biol - Advances in Internal Medicine DOI 10.1007/5584_2016_26 # Springer International Publishing Switzerland 2016 Endocrine Hypertension: A Practical Approach Joseph M. Pappachan and Harit N. Buch Abstract Elevated blood pressure resulting from few endocrine disorders (endo- crine hypertension) accounts for a high proportion of cases of secondary hypertension. Although some features may be suggestive, many cases of endocrine hypertension remain silent until worked up for the disease. A majority of cases result from primary aldosteronism. Other conditions that can cause endocrine hypertension are: congenital adrenal hyperplasia, Liddle syndrome, pheochromocytomas, Cushing’s syndrome, acromeg- aly, thyroid diseases, primary hyperparathyroidism and iatrogenic hor- mone manipulation. Early identification and treatment of the cause of endocrine hypertension may help to reduce morbidity and mortality related to these disorders. This article gives a comprehensive and practical approach to the diagnosis and management of endocrine hypertension. Keywords Endocrine hypertension • Primary aldosteronism • Congenital adrenal hyperplasia • Liddle syndrome • Pheochromocytoma • Cushing’s syndrome • Acromegaly • Thyroid disease • Primary hyperparathyroidism 1 Introduction hypertension is approximately 40 % among adults over the age of 25 years and contributes Hypertension is a chronic condition with multi- to 45–50 % of deaths due to heart disease and system involvement and is associated with high stroke (World Health Organization. Obesity and morbidity and mortality. The prevalence of overweight 2015). Although the prevalence of hypertension is high in the general population, only in around 10 % of cases an underlying spe- cific cause can be identified (secondary hyperten- J.M. Pappachan (*) and H.N. Buch Department of Endocrinology & Diabetes, New Cross sion), of which the majority are related to renal Hospital, The Royal Wolverhampton Hospital NHS Trust, and endocrine disorders (Young 2015).
    [Show full text]